"Investors are watching Doximity ( NYSE:DOCS | DOCS Price Prediction) ahead of its fiscal fourth-quarter results due after the close today. After a brutal six months for shareholders, this report needs to rebuild credibility on the forward guide."
"Last quarter, Doximity beat on the top and bottom line. Revenue of $185.05 million grew 9.76% YoY and non-GAAP EPS of $0.46 topped consensus. Yet the stock fell 16.78% on the earnings report as Q4 guidance missed Street expectations."
"Management said on the Q3 call that no AI revenue is currently included in guidance, with a commercial product expected later in 2026. With 300,000+ AI users and 100+ health systems already on the suite, covering 180,000 prescribers, any pricing framework or pharma-facing product timeline matters."
"Adjusted EBITDA margin ran at 60.2% in Q3, but GAAP net income fell 18.14% YoY as R&D surged 54% and stock-based comp nearly doubled. Management has flagged a 50% EBITDA margin fl"
Doximity is set to report fiscal fourth-quarter results after the close, with investors seeking renewed credibility after a guidance miss. The prior quarter showed revenue of $185.05 million, up 9.76% year over year, and non-GAAP EPS of $0.46 above consensus, yet the stock dropped 16.78% due to Q4 guidance falling short. Shares have since declined sharply, and CFO Anna Bryson resigned on April 28, 2026, with Siddharth Sitaram serving as interim CFO. The board authorized a $500 million open-ended buyback. Investors will focus on AI commercialization timing, confirmation of calendar 2026 reacceleration, and whether margin trends improve despite rising R&D and stock-based compensation.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]